In this photo illustration, the Merck & Co., Inc. logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Aug 29 (Reuters) - Merck (MRK.N), opens new tab has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

The stock's fall snapped a five-day winning streak.

Merck KGaA (0O14 – Research Report) received a Buy rating and a €205.00 price target from Goldman Sachs analyst James Quigley today. The ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.